TG Therapeutics

is a biopharmaceutical company focused on the development of
novel treatments for B-cell malignancies and autoimmune diseases.

Click for full image >>

For Investors

NASDAQ: TGTX

Stock Quote at: Jun 23, 4:00PM EDT

Last: $11.95

Change: ($0.05) (0.42%)

Quotes provided by Google - Min 15 minute delay

News & Events

6.14.17

TG Therapeutics Announces Follow-Up Data from the Combination of TGR-1202 plus ibrutinib in Patients with Relapsed or Refractory CLL and MCL at the 14th International Conference on Malignant Lymphoma

6.15.17

TG Therapeutics Announces Follow-Up Data from the Triple Combination of TG-1101, TGR-1202 and Bendamustine in Patients with DLBCL and FL at the 14th International Conference on Malignant Lymphoma

Quick Links